1887

Journal of Medical Microbiology logo

Volume 62, Issue 1

Genetic and antigenic characterization of invasive endemic serogroup B from Ontario, Canada, in 2001–2010 Free

Abstract

This study examined the antigenic and genetic diversity of serogroup B (MenB) recovered from invasive meningococcal disease (IMD) cases in Ontario, Canada, over the period 2001–2010 during which no MenB outbreaks had occurred. MenB was found to be responsible for 39 % of all IMD cases, with the remaining cases caused mainly by serogroups Y (28 %), C (23.5 %) and W135 (8 %). One hundred and ninety-three individual MenB case isolates were collected and characterized. Of the 88 sequence types (STs) identified, 75 were grouped into 14 known clonal complexes (CCs), whilst 13 STs were not assigned to any known CC. Fifty-seven different PorA genotypes and 88 STs defined the diversity of invasive MenB in Ontario, which supported the endemic nature of MenB disease in Ontario. Despite the presence of the hypervirulent ST-41/44 and ST-32 CCs, no single ST was predominant and responsible for a large number of IMD cases. Although the Québec outbreak clone of ST-269 was also found in Ontario, the 20 case isolates were genetically diverse: they grouped into seven STs and did not have a predominant PorA genotype. e analysis identified a new CC responsible for 14.5 % of the MenB case isolates. The six most common PorA variable region 2 (VR2) genotypes (VR2-9, -4, -14, -16, -13-1 and -16-3) were found in 67 % of invasive MenB isolates.

  • Received:
  • Accepted:
  • Published Online:
© 2013 Public Health Agency of Canada and Public Health Ontario
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.050369-0
2013-01-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/1/46.html?itemId=/content/journal/jmm/10.1099/jmm.0.050369-0&mimeType=html&fmt=ahah

References

  1. Abdillahi H., Poolman J. T. 1987; Whole cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett 48:367–371 [View Article]
     [Google Scholar]
  2. Al-Tawfiq J. A., Clark T. A., Memish Z. A. 2010; Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J Travel Med 17:Suppl.3–8 [View Article][PubMed]
     [Google Scholar]
  3. Ashton F. E., Caugant D. A. 2001; The panmictic nature of Neisseria meningitidis serogroup B during a period of endemic disease in Canada. Can J Microbiol 47:283–289[PubMed] [CrossRef]
     [Google Scholar]
  4. Ashton F. E., Ryan J. A., Borczyk A., Caugant D. A., Mancino L., Huang D. 1991a; Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 29:2489–2493[PubMed]
     [Google Scholar]
  5. Ashton F. E., Mancino L., Ryan A. J., Poolman J. T., Abdillahi H., Zollinger W. D. 1991b; Serotypes and subtypes of Neisseria meningitidis serogroup B strains associated with meningococcal disease in Canada, 1977–1989. Can J Microbiol 37:613–617 [View Article][PubMed]
     [Google Scholar]
  6. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., Comanducci M. 2009; Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27:2794–2803 [View Article][PubMed]
     [Google Scholar]
  7. Bjune G., Høiby E. A., Grønnesby J. K., Arnesen O., Fredriksen J. H., Halstensen A., Holten E., Lindbak A. K., Nøkleby H. other authors 1991; Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093–1096 [View Article][PubMed]
     [Google Scholar]
  8. Brooks R., Woods C. W., Benjamin D. K. Jr, Rosenstein N. E. 2006; Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994–2002. Clin Infect Dis 43:49–54 [View Article][PubMed]
     [Google Scholar]
  9. Caugant D. A. 1998; Population genetics and molecular epidemiology of Neisseria meningitidis . APMIS 106:505–525 [View Article][PubMed]
     [Google Scholar]
  10. Chiou C.-S., Liao J.-C., Liao T.-L., Li C.-C., Chou C.-Y., Chang H.-L., Yao S.-M., Lee Y.-S. 2006; Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan. BMC Infect Dis 6:25 [View Article][PubMed]
     [Google Scholar]
  11. Clarke S. C., Diggle M. A., Mölling P., Unemo M., Olcén P. 2003; Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?. Vaccine 21:2468–2473 [View Article][PubMed]
     [Google Scholar]
  12. de Filippis I., Gopalan V., Huyen Y. 2011; A web-based resource for the determination of PorA VR3 alleles of Neisseria meningitidis.. Infect Gene Evol 11:248–249 [CrossRef]
     [Google Scholar]
  13. de Moraes J. C., Perkins B. A., Camargo M. C., Hidalgo N. T., Barbosa H. A., Sacchi C. T., Landgraf I. M., Gattas V. L., Vasconcelos H. G. other authors 1992; Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340:1074–1078 [View Article][PubMed]
     [Google Scholar]
  14. Deeks S. L., Kertesz D., Ryan A., Johnson W., Ashton F. 1997; Surveillance of invasive meningococcal disease in Canada, 1995–1996. Can Commun Dis Rep 23:121–125[PubMed]
     [Google Scholar]
  15. Feavers I. M., Gray S. J., Urwin R., Russell J. E., Bygraves J. A., Kaczmarski E. B., Maiden M. C. J. 1999; Multilocus sequence typing and antigen gene sequencing in the investigation of a meningococcal disease outbreak. J Clin Microbiol 37:3883–3887[PubMed]
     [Google Scholar]
  16. Finne J., Leinonen M., Mäkelä P. H. 1983; Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 322:355–357 [View Article][PubMed]
     [Google Scholar]
  17. Francisco A. P., Bugalho M., Ramirez M., Carriço J. A. 2009; Global optimal eBURST analysis of multilocus typing data using a graphic matroid approach. BMC Bioinformatics 10:152 [View Article][PubMed]
     [Google Scholar]
  18. Frasch C. E., Zollinger W. D., Poolman J. T. 1985; Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7:504–510 [View Article][PubMed]
     [Google Scholar]
  19. Giuliana M. M., Adu-Bobie J., Caoanducci M., Arico B., Savino S., Santini L., Brunelli B., Bambini S., Biolchi A. other authors 2006; A universal vaccine for serogroup B meningococcus.. Proc Natl Acad Sci U S A 103:10834–10839 [View Article]
     [Google Scholar]
  20. Hao W., Ma J. H., Warren K., Tsang R. S. W., Low D. E., Jamieson F. B., Alexander D. C. 2011; Extensive genomic variation within clonal complexes of Neisseria meningitidis . Genome Biol Evol 3:1406–1418 [View Article][PubMed]
     [Google Scholar]
  21. Harrison L. H., Shutt K. A., Schmink S. E., Marsh J. W., Harcourt B. H., Wang X., Whitney A. M., Stephens D. S., Cohn A. A. other authors 2010; Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era – United States, 2000–2005. J Infect Dis 201:1208–1224 [View Article][PubMed]
     [Google Scholar]
  22. Harrison O. B., Brueggemann A. B., Caugant D. A., van der Ende A., Frosch M., Gray S., Heuberger S., Krizova P., Olcen P. other authors 2011; Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review. Microbiology 157:2181–2195 [View Article][PubMed]
     [Google Scholar]
  23. Holmes E. C., Urwin R., Maiden M. C. 1999; The influence of recombination on the population structure and evolution of the human pathogen Neisseria meningitidis . Mol Biol Evol 16:741–749 [View Article][PubMed]
     [Google Scholar]
  24. Howitz M., Krause T. G., Simonsen J. B., Hoffmann S., Frisch M., Nielsen N. M., Robbins J., Schneerson R., Mølbak K., Miller M. A. 2007; Lack of association between group B meningococcal disease and autoimmune disease. Clin Infect Dis 45:1327–1334 [View Article][PubMed]
     [Google Scholar]
  25. Johswich K. O., Zhou J., Law D. K. S., St Michael F., McCaw S. E., Jamieson F. B., Cox A. D., Tsang R. S. W., Gray-Owen S. D. 2012; Invasive potential of nonencapsulated disease isolates of Neisseria meningitidis . Infect Immun 80:2346–2353 [View Article][PubMed]
     [Google Scholar]
  26. Joseph B., Schneiker-Bekel S., Schramm-Glück A., Blom J., Claus H., Linke B., Schwarz R. F., Becker A., Goesmann A. other authors 2010; Comparative genome biology of a serogroup B carriage and disease strain supports a polygenic nature of meningococcal virulence. J Bacteriol 192:5363–5377 [View Article][PubMed]
     [Google Scholar]
  27. Kertesz D., Coulthart M., Ryan A., Johnson W., Ashton F. 1998; Serogroup B electrophoresis type 15 Neisseria meningitidis . Can J Infect Dis Med Microbiol 177:1754–1757
     [Google Scholar]
  28. Ladhani S. N., Flood J. S., Ramsay M. E., Campbell H., Gray S. J., Kaczmarski E. B., Mallard R. H., Guiver M., Newbold L. S., Borrow R. 2012; Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 30:3710–3716 [View Article][PubMed]
     [Google Scholar]
  29. Law D. K. S., Lorange M., Ringuette L., Dion R., Giguère M., Henderson A. M., Stoltz J., Zollinger W. D., De Wals P., Tsang R. S. W. 2006; Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 44:2743–2749 [View Article][PubMed]
     [Google Scholar]
  30. Lo H., Tang C. M., Exley R. M. 2009; Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 9:418–427 [View Article][PubMed]
     [Google Scholar]
  31. Lucidarme J., Comanducci M., Findlow J., Gray S. J., Kaczmarski E. B., Guiver M., Kugelberg E., Vallely P. J., Oster P. other authors 2009; Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol 47:3577–3585 [View Article][PubMed]
     [Google Scholar]
  32. Lucidarme J., Comanducci M., Findlow J., Gray S. J., Kaczmarski E. B., Guiver M., Vallely P. J., Oster P., Pizza M. other authors 2010; Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 17:919–929 [View Article][PubMed]
     [Google Scholar]
  33. Lucidarme J., Tan L., Exley R. M., Findlow J., Borrow R., Tang C. M. 2011; Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 18:1002–1014 [View Article][PubMed]
     [Google Scholar]
  34. Maiden M. C. J., Urwin R. 2006; Population dynamics of bacterial pathogens. In Evolution of Microbial Pathogens pp. 35–53 Edited by Seifert H. S. Washington, DC: American Society for Microbiology;
     [Google Scholar]
  35. Maiden M. C. J., Bygraves J. A., Feil E., Morelli G., Russell J. E., Urwin R., Zhang Q., Zhou J., Zurth K. other authors 1998; Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95:3140–3145 [View Article][PubMed]
     [Google Scholar]
  36. Marri P. R., Paniscus M., Weyand N. J., Rendón M. A., Calton C. M., Hernández D. R., Higashi D. L., Sodergren E., Weinstock G. M. other authors 2010; Genome sequencing reveals widespread virulence gene exchange among human Neisseria species. PLoS ONE 5:e11835 [View Article][PubMed]
     [Google Scholar]
  37. Martin D. R., Ruijne N., McCallum L., O’Hallahan J., Oster P. 2006; The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 13:486–491 [View Article][PubMed]
     [Google Scholar]
  38. Mayer L. W., Reeves M. W., Al-Hamdan N., Sacchi C. T., Taha M. K., Ajello G. W., Schmink S. E., Noble C. A., Tondella M. L. other authors 2002; Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 185:1596–1605 [View Article][PubMed]
     [Google Scholar]
  39. Navarro C., Deeks S. L., Medagha A., Tsang R. S. W. 2007; Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. Can Commun Dis Rep 33:1–15[PubMed]
     [Google Scholar]
  40. Oster P., Lennon D., O’Hallahan J., Mulholland K., Reid S., Martin D. 2005; MeNZB tm : a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191–2196 [View Article][PubMed]
     [Google Scholar]
  41. Patrick D. M., Champagne S., Goh S. H., Arsenault G., Thomas E., Shaw C., Rahim T., Taha F., Bigham M. other authors 2003; Neisseria meningitidis carriage during an outbreak of serogroup C disease. Clin Infect Dis 37:1183–1188 [View Article][PubMed]
     [Google Scholar]
  42. Pillai S., Howell A., Alexander K., Bentley B. E., Jiang H. Q., Ambrose K., Zhu D., Zlotnick G. 2005; Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23:2206–2209 [View Article][PubMed]
     [Google Scholar]
  43. Pollard A. J., Tam T. W. S. National Advisory Committee on Immunisation (NACI) 2001; An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep 27:2–36[PubMed]
     [Google Scholar]
  44. Richmond P. C., Marshall H. S., Nissen M. D., Jiang Q., Jansen K. U., Garcés-Sánchez M., Martinón-Torres F., Beeslaar J., Szenborn L. other authors 2012; Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12:597–607 [View Article][PubMed]
     [Google Scholar]
  45. Riou J. Y., Guibourdenche M. 1992 Laboratory Methods, Neisseria and Branhamella Paris, France: Institut Pasteur;
     [Google Scholar]
  46. Robbins J. B., Schneerson R., Xie G., Hanson L. A., Miller M. A. 2011; Capsular polysaccharide vaccine for group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2. Proc Natl Acad Sci U S A 108:17871–17875 [View Article][PubMed]
     [Google Scholar]
  47. Rosenstein N. E., Perkins B. A., Stephens D. S., Popovic T., Hughes J. M. 2001; Meningococcal disease. N Engl J Med 344:1378–1388 [View Article][PubMed]
     [Google Scholar]
  48. Sacchi C. T., Lemos A. P., Brandt M. E., Whitney A. M., Melles C. E. A., Solari C. A., Frasch C. E., Mayer L. W. 1998; Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol 5:845–855[PubMed]
     [Google Scholar]
  49. Santolaya M. E., O’Ryan M. L., Valenzuela M. T., Prado V., Vergara R., Muñoz A., Toneatto D., Graña G., Wang H. other authors 2012; Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379:617–624 [View Article][PubMed]
     [Google Scholar]
  50. Sierra G. V. G., Campa H. C., Varcacel N. M., Garcia I. L., Izquierdo P. L., Sotolongo P. F., Casanueva G. V., Rico C. O., Rodriguez C. R., Terry M. H. 1991; Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14:195–207, discussion 208–210[PubMed]
     [Google Scholar]
  51. Squires S. G., Pelletier L., Mungai M., Tsang R., Collins F., Stoltz J. 2000; Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998. Can Commun Dis Rep 26:177–182[PubMed]
     [Google Scholar]
  52. Squires S. G., Deeks S. L., Tsang R. S. W. 2004; Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001. Can Commun Dis Rep 30:17–28[PubMed]
     [Google Scholar]
  53. Takahashi H., Kuroki T., Watanabe Y., Tanaka H., Inouye H., Yamai S., Watanabe H. 2004; Characterization of Neisseria meningitidis isolates collected from 1974 to 2003 in Japan by multilocus sequence typing. J Med Microbiol 53:657–662 [View Article][PubMed]
     [Google Scholar]
  54. Tsang R. S. W., Squires S. G., Zollinger W. D., Ashton F. E. 2002; Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001. Can J Infect Dis Med Microbiol 13:391–396[PubMed]
     [Google Scholar]
  55. Tsang R. S. W., Kiefer L., Law D. K. S., Stoltz J., Shahin R., Brown S., Jamieson F. 2003; Outbreak of serogroup C meningococcal disease caused by a variant of Neisseria meningitidis serotype 2a ET-15 in a community of men who have sex with men. J Clin Microbiol 41:4411–4414 [View Article][PubMed]
     [Google Scholar]
  56. Tsang R. S. W., Tsai C. M., Zhu P., Ringuette L., Lorange M., Law D. K. S. 2004; Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada. J Clin Microbiol 42:1460–1465 [View Article][PubMed]
     [Google Scholar]
  57. Tsang R. S. W., Law D. K. S., Henderson A. M., Blake M. L., Stoltz J. 2006; Increase in serogroup C meningococcal disease in Canada is associated with antigenic changes in the protein antigens of the ET-15 clone of Neisseria meningitidis . J Infect Dis 194:1791–1792, author reply 1792–1793 [View Article][PubMed]
     [Google Scholar]
  58. Tsang R. S. W., Henderson A. M., Cameron M. L., Tyler S. D., Tyson S., Law D. K. S., Stoltz J., Zollinger W. D. 2007; Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol 45:1753–1758 [View Article][PubMed]
     [Google Scholar]
  59. Tsang R. S. W., Tsai C. M., Henderson A. M., Tyler S., Law D. K. S., Zollinger W., Jamieson F. 2008; Immunochemical studies and genetic background of two Neisseria meningitidis isolates expressing unusual capsule polysaccharide antigens with specificities of both serogroup Y and W135. Can J Microbiol 54:229–234 [View Article][PubMed]
     [Google Scholar]
  60. Tsang R. S. W., Lefebvre B., Jamieson F. B., Gilca R., Deeks S. L., Zhou J. 2012; Identification and proposal of a potentially new clonal complex that is a common cause of MenB disease in central and eastern Canada. Can J Microbiol 58:1236–1240[PubMed] [CrossRef]
     [Google Scholar]
  61. Tyrrell G. J., Chui L., Johnson M., Chang N., Rennie R. P., Talbot J. A. Edmonton Meningococcal Study Group 2002; Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis 8:519–521 [View Article][PubMed]
     [Google Scholar]
  62. Vedros N. A. 1987; Development of meningococcal serogroups. In Evolution of Meningococcal Disease pp. 33–37 Edited by Vedros N. A. Boca Raton, FL: CRC Press;
     [Google Scholar]
  63. Vogel U., Szczepanowski R., Claus H., Jünemann S., Prior K., Harmsen D. 2012; Ion torrent personal genome machine sequencing for genomic typing of Neisseria meningitidis for rapid determination of multiple layers of typing information. J Clin Microbiol 50:1889–1894 [View Article][PubMed]
     [Google Scholar]
  64. Wang J. F., Caugant D. A., Morelli G., Koumaré B., Achtman M. 1993; Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis . J Infect Dis 167:1320–1329 [View Article][PubMed]
     [Google Scholar]
  65. Warshawsky B., Desai S., Langley J. 2009; Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement. Can Commun Dis Rep 36:1–40
     [Google Scholar]
  66. Watkins K. M., Deeks S. L., Medqaglia A., Tsang R. S. W. 2006; Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003. Can Commun Dis Rep 32:97–107[PubMed]
     [Google Scholar]
  67. Yang L., Shao Z., Zhang X., Xu L., Peng J., Xu X., Liang X., Qi Y., Jin Q. 2008; Genotypic characterization of Neisseria meningitidis serogroup B strains circulating in China. J Infect 56:211–218 [View Article][PubMed]
     [Google Scholar]
  68. Yazdankhah S. P., Kriz P., Tzanakaki G., Kremastinou J., Kalmusova J., Musilek M., Alvestad T., Jolley K. A., Wilson D. J. other authors 2004; Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 42:5146–5153 [View Article][PubMed]
     [Google Scholar]
  69. Zhou J., Lefebvre B., Deng S., Gilca R., Deceuninck G., Law D. K. S., De Wals P., Tsang R. S. W. 2012; Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J Clin Microbiol 50:1545–1551 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.050369-0
Loading
Genetic and antigenic characterization of invasive endemic serogroup B Neisseria meningitidis from Ontario, Canada, in 2001–2010
J. Med. Microbiol. 62, 46 (2013); https://doi.org/10.1099/jmm.0.050369-0
/content/journal/jmm/10.1099/jmm.0.050369-0
/content/journal/jmm/10.1099/jmm.0.050369-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error